Methods and apparatus for optimal remote ischemic preconditioning (ORIP) for preventing ischemia-reperfusion injuries to organs
AssigneeNeoCardium, Limited
InventorFazal Raheman
Life of this patent
Estimating the term…
Loading patent…
AssigneeNeoCardium, Limited
InventorFazal Raheman
Estimating the term…
Ischemia-reperfusion injury commonly results from any surgical procedure requiring stopping of blood supply to an organ followed by reperfusion such as in heart bypass, angioplasty or organ transplant. The invention discloses a method to harness the innate power of repetitive transient ischemia in protecting organs against imminent ischemia-reperfusion, or any patho-physiological insults. This method of optimal remote ischemic preconditioning (ORIP) comprises of utilizing a pair of programmable pneumatic cuffs that inflate/deflate alternately occluding blood circulation to each of the limbs for pre-defined time intervals. The apparatus delivers maximal ORIP dose in shortest possible time either as an EMS procedure during patient transportation to hospital, as elective pre-surgery treatment, or in critical care for preventing multiple-organ-dysfunction-syndrome. ORIP can be self-administered and remotely monitored by clinician especially in chronic patients for homeostasis of malfunctioning target organs. ORIP may also be deployed as adjunct in angioplasty, gene/stem cell heart repair therapies.
An Optimal Remote Ischemic Preconditioning (ORIP) method for non-invasively inducing transient, repetitive and alternating ischemia and reperfusion of at least a pair of remote organs including a first limb and a second contralateral limb in a treatment regimen that renders maximal systemic protection to one or more of other targeted body organs of a patient in minimal possible dosing time and patient discomfort, either against acute injury caused by reperfusion of the target organ(s) after prolonged ischemia, or for increasing the threshold of the target organs to withstand acute or chronic physiological and pathological insults resulting therein in release of ischemia triggered cellular modulators (ITCMs) optimally that cause improvement of physiological functions of malfunctioning target organs comprising the steps of:
Dependencies are inferred from the claim text.